Moving forward - Essential questions for the next 10 years

Richard B. Lipton, Fred D. Sheftell

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The future is bright for migraine sufferers. For acute treatment, CGRP antagonists and combination products will provide more complete, longer lasting, and safer relief. "Designer drugs" for migraine prevention will be identified based on their ability to block cortical spreading depression and will improve migraine treatment. Genetic and environmental risk factors that promote migraine progression will be identified and preventing progression will become a standard goal in treatment. Some of the devices intended to treat migraine will be approved and will provide important options for sufferers seeking to avoid drugs. Clinical trials that evaluate behavioral and pharmacologic interventions and their impact on patient centered outcomes will emerge. The emergence of novel treatments, when coupled with strategies for individualizing and optimizing treatment while maximizing adherence, will result in ever improving patient outcomes.

Original languageEnglish (US)
JournalHeadache
Volume49
Issue numberSUPPL. 1
DOIs
StatePublished - Feb 2009

Fingerprint

Migraine Disorders
Designer Drugs
Cortical Spreading Depression
Therapeutics
Clinical Trials
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • Future direction
  • Migraine science
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Moving forward - Essential questions for the next 10 years. / Lipton, Richard B.; Sheftell, Fred D.

In: Headache, Vol. 49, No. SUPPL. 1, 02.2009.

Research output: Contribution to journalArticle

Lipton, Richard B. ; Sheftell, Fred D. / Moving forward - Essential questions for the next 10 years. In: Headache. 2009 ; Vol. 49, No. SUPPL. 1.
@article{3c05aef68544414591caa116fa970929,
title = "Moving forward - Essential questions for the next 10 years",
abstract = "The future is bright for migraine sufferers. For acute treatment, CGRP antagonists and combination products will provide more complete, longer lasting, and safer relief. {"}Designer drugs{"} for migraine prevention will be identified based on their ability to block cortical spreading depression and will improve migraine treatment. Genetic and environmental risk factors that promote migraine progression will be identified and preventing progression will become a standard goal in treatment. Some of the devices intended to treat migraine will be approved and will provide important options for sufferers seeking to avoid drugs. Clinical trials that evaluate behavioral and pharmacologic interventions and their impact on patient centered outcomes will emerge. The emergence of novel treatments, when coupled with strategies for individualizing and optimizing treatment while maximizing adherence, will result in ever improving patient outcomes.",
keywords = "Future direction, Migraine science, Treatment",
author = "Lipton, {Richard B.} and Sheftell, {Fred D.}",
year = "2009",
month = "2",
doi = "10.1111/j.1526-4610.2008.01362.x",
language = "English (US)",
volume = "49",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Moving forward - Essential questions for the next 10 years

AU - Lipton, Richard B.

AU - Sheftell, Fred D.

PY - 2009/2

Y1 - 2009/2

N2 - The future is bright for migraine sufferers. For acute treatment, CGRP antagonists and combination products will provide more complete, longer lasting, and safer relief. "Designer drugs" for migraine prevention will be identified based on their ability to block cortical spreading depression and will improve migraine treatment. Genetic and environmental risk factors that promote migraine progression will be identified and preventing progression will become a standard goal in treatment. Some of the devices intended to treat migraine will be approved and will provide important options for sufferers seeking to avoid drugs. Clinical trials that evaluate behavioral and pharmacologic interventions and their impact on patient centered outcomes will emerge. The emergence of novel treatments, when coupled with strategies for individualizing and optimizing treatment while maximizing adherence, will result in ever improving patient outcomes.

AB - The future is bright for migraine sufferers. For acute treatment, CGRP antagonists and combination products will provide more complete, longer lasting, and safer relief. "Designer drugs" for migraine prevention will be identified based on their ability to block cortical spreading depression and will improve migraine treatment. Genetic and environmental risk factors that promote migraine progression will be identified and preventing progression will become a standard goal in treatment. Some of the devices intended to treat migraine will be approved and will provide important options for sufferers seeking to avoid drugs. Clinical trials that evaluate behavioral and pharmacologic interventions and their impact on patient centered outcomes will emerge. The emergence of novel treatments, when coupled with strategies for individualizing and optimizing treatment while maximizing adherence, will result in ever improving patient outcomes.

KW - Future direction

KW - Migraine science

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=58649092144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58649092144&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.2008.01362.x

DO - 10.1111/j.1526-4610.2008.01362.x

M3 - Article

VL - 49

JO - Headache

JF - Headache

SN - 0017-8748

IS - SUPPL. 1

ER -